Literature DB >> 3621107

Acute arrhythmogenicity of doxorubicin administration.

J S Steinberg, A J Cohen, A G Wasserman, P Cohen, A M Ross.   

Abstract

The magnitude of acute arrhythmogenicity of doxorubicin administration has not been characterized. In this study the type and frequency of cardiac arrhythmia is determined in the first hour and first 24 hours following doxorubicin given as a 10-minute infusion. Twenty-nine patients with diverse malignancies were studied with Holter monitors on 33 postdoxorubicin days. Control recordings were made on days remote from doxorubicin treatment. The frequency of arrhythmia that could be attributed to doxorubicin was low: 3% of studies in the first hour postinfusion and 24% of studies in 1 to 24 hours postinfusion. The most commonly seen arrhythmia was an increased frequency of ventricular premature beats. Arrhythmia following doxorubicin infusion is rare in the first hour and more common in the remainder of the first 24 hours postinfusion. There are no acute or long-term adverse consequences related to the appearance of arrhythmia due to doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621107     DOI: 10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer.

Authors:  Todd Swanson; Inga S Grills; Hong Ye; Amy Entwistle; Melanie Teahan; Nicola Letts; Di Yan; Joana Duquette; Frank A Vicini
Journal:  Am J Clin Oncol       Date:  2013-02       Impact factor: 2.339

2.  Comparison of acute effects of anthracyclines on cardiac electrophysiological parameters of isolated guinea-pig hearts.

Authors:  G Stark; U Stark; H Samonigg; K Kasparek; A Lueger; S Nagl; H Bertuch; E Pilger; H A Tritthart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 5.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

6.  Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.

Authors:  András Csaba Nagy; Zsuzsanna Cserép; Edina Tolnay; Tamás Nagykálnai; Tamás Forster
Journal:  Pathol Oncol Res       Date:  2008-03-15       Impact factor: 3.201

7.  Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts).

Authors:  R P Gehdoo
Journal:  Indian J Anaesth       Date:  2009-02

8.  Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).

Authors:  Joffrey Ducroq; H Moha ou Maati; S Guilbot; S Dilly; E Laemmel; C Pons-Himbert; J F Faivre; P Bois; O Stücker; M Le Grand
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

9.  Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.

Authors:  Sara Vandenwijngaert; Melissa Swinnen; Ann-Sophie Walravens; Manu Beerens; Hilde Gillijns; Ellen Caluwé; Robert E Tainsh; Daniel I Nathan; Kaitlin Allen; Peter Brouckaert; Jozef Bartunek; Marielle Scherrer-Crosbie; Kenneth D Bloch; Donald B Bloch; Stefan P Janssens; Emmanuel S Buys
Journal:  Antioxid Redox Signal       Date:  2016-09-08       Impact factor: 8.401

10.  Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.

Authors:  Saadettin Kilickap; Bunyamin Yavuz; Sercan Aksoy; Levent Sahiner; Murat Dincer; Hakan Harputluoglu; Mustafa Erman; Kudret Aytemir; Lale Tokgozoglu; Ibrahim Barista
Journal:  Med Oncol       Date:  2008-04-15       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.